Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in Kidney Transplant Recipients With Late Antibody-Mediated Rejection
NCT07613359Phase 2Not yet recruiting
- Sponsor
- Takeda
- Start
- Oct 2026
- Primary completion
- Jan 2029
- Countries
- 5
01
Overview
A Phase 2 trial of mezagitamab in antibody mediated rejection (AMR), sponsored by Takeda. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
mezagitamab
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT07613359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07613359.